Cynapsus Therapeutics Reports Second Quarter 2015 Financial Results and Recent Developments
August 14, 2021
TORONTO – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (“Cynapsus” or the “Company”), a specialty Central Nervous System (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced financial results for the three and six months ended June 30, 2015. Unless specified otherwise, all amounts are in Canadian dollars.
“In the first six months of 2015, we have made significant progress advancing our strategic plan, including work related to the commencement of Phase 3 clinical trials for APL-130277. Importantly, we also raised gross proceeds of approximately $110 million through the completion of a $21 million private placement in March and an $89 million U.S. Re-IPO in June, the latter of which included a listing on NASDAQ Global Market under the stock symbol “CYNA”. Looking forward, we remain focused on the completion of Phase 3 bridging, efficacy and safety studies of APL-130277 over the next 12 to 16 months, as well as pre-approval commercialization efforts in the U.S. market, and initial regulatory and clinical activities for European market registration,” stated Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus.
Financial Highlights
• Cash as of June 30, 2022 of $111,455,042 (December 31, 2014: $17,448,497).
• Cash used in operating activities of $13,258,555 for the six months ended June 30, 2022 (six months ended June 30, 2014: $4,942,221).
• Net loss of $10,958,509 for the three months ended June 30, 2022 (three months ended June 30, 2014: $2,816,058).
• Net loss of $16,052,941 for the six months ended June 30, 2022 (six months ended June 30, 2014: $4,026,330).
• Reported 12,114,364 common shares outstanding as of June 30, 2022 (December 31, 2014: 5,020,090 common shares), as adjusted for the 16:1 share consolidation completed on May 15, 2015.
Operational Highlights
• Completed End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (“FDA”). On February 4, 2015, Cynapsus held its End-of-Phase 2 meeting with the FDA. For development of APL-130277 in the U.S., the Company will follow Section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act. The drug substance (apomorphine) in APL-130277 is identical to the active pharmaceutical ingredient in the FDA approved subcutaneous injection, Apokyn®, and APL-130277 is designed for similar usage but potentially for a broader range of PD patients. The Section 505(b)(2) regulatory pathway will require the Company to provide statistically significant clinical evidence that PD patients experience improvement in their motor function as a result of delivery of apomorphine via the sublingual thin film route compared to placebo.
• Reported Details for the Company’s Phase 3 Pivotal Program. On March 11, 2015, following the End-of-Phase 2 meeting with the U.S. FDA, the Company announced that an agreement was reached on the design, duration and size for the Phase 3 program clinical studies, as well as for primary and key secondary endpoints. As a result, the Company has initiated a pivotal Phase 3 program evaluating the safety and efficacy of APL-130277 in PD patients.
• Appointed a new Director to the Board of Directors. On March 12, 2015, Tamar Howson was appointed to the Board of Directors. Ms. Howson is a seasoned business development executive within the pharmaceutical industry, having formerly served as Senior Vice President at both Bristol-Myers Squibb and SmithKline Beecham. Ms. Howson currently serves as a business development and strategy consultant to biopharmaceutical companies and she also serves as a director at Oxigene Pharmaceuticals and Organovo. She has formerly served as a director at several biotechnology companies, including Actavis, Ariad, Idenix Pharmaceuticals, NPS Pharmaceuticals, SkyePharma and Warner Chilcott.
• Presented Data from a Pharmacokinetic Subgroup of the Phase 2 CTH-105 Study at the American Academy of Neurology (AAN) Annual Meeting. On April 22, 2015, the Company presented data at AAN that demonstrated that a minimum efficacious plasma threshold of apomorphine was required to convert a patient from the OFF state to the ON state. APL-130277 reached this threshold in as early as 10 minutes and levels were maintained over this threshold through 90 minutes after dosing. This translated to clinically meaningful improvement in motor function as assessed by the MDS-UPDRS Part III score.
• Completed Private Placement Financing for Gross Proceeds of $21 Million. On March 31, 2015, the Company announced the completion of a private placement of 1,377,467 common shares for gross proceeds of approximately $21.0 million (approximately US$17 million). The financing was led by funds associated with OrbiMed, Aisling Capital and Venrock, with participation from various other institutional investors, including existing shareholders Broadfin Capital, Sphera Funds Management, Pura Vida Investments, DAFNA Capital Management and Dexcel Pharma Technologies Ltd./Dexxon Holdings Ltd.
• Announced Issuance of U.S. Patent No. 9,044,475. On June 4, 2015, the Company announced the issuance of a U.S. Patent No. 9,044,475 providing broad coverage for sublingual apomorphine. This patent is solely owned by Cynapsus and granted with claims that provide the Company with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic pH neutralizing agent and a permeation enhancer in a sublingual film. This patent is scheduled to expire in June of 2030 and covers APL-130277 and related formulations. The issued patent is the third to issue as a U.S. patent from the Company’s patent application filings directed to sublingual apomorphine therapies.
• Completed U.S. Re-IPO for Gross Proceeds of $89.3 Million and Commenced Trading on NASDAQ. On June 18, 2015, following the pricing of the Company’s public offering in the United States, the Company’s common shares commenced trading on the NASDAQ Global Market under the symbol “CYNA”. The Company’s common shares also continue to be listed on the Toronto Stock Exchange under the symbol “CTH.” On June 23, 2015, the Company announced the completion of a public offering in the United States of 5,175,000 common shares for total gross proceeds of approximately $89.3 million (approximately US$72.5 million), including the exercise in full of the underwriters’ option to purchase additional common shares.
• Presented Data at the 19th International Congress of Parkinson's Disease and Movement Disorders (MDS). On June 25, 2015, the Company announced that it presented data from clinical trials of APL-130277 at MDS in San Diego, California, showing APL-130277 significantly improved PD symptoms (as measured by MDS-UPDRS Part III), rapidly turning patients from the OFF to ON state and was generally safe and well tolerated.
• Announced the First Patient Enrolled in the CTH-300 Efficacy Study. On June 29, 2015, the Company announced enrollment of the first patient in the CTH-300 clinical trial, a pivotal Phase 3 study to examine the efficacy, safety and tolerability of APL-130277 for the acute treatment of OFF episodes in patients with PD. The CTH-300 trial is a double-blind, placebo-controlled, parallel-design study with an estimated enrollment of 126 PD patients in 35 centers who have at least one OFF episode every 24 hours, with total OFF time of at least two hours per day.
Results of Annual and Special Meeting of Shareholders
In respect of the Annual and Special Meeting of shareholders of the Company held on May 7, 2022 (the “Meeting”), the following sets forth a brief description of each matter which was voted upon at the Meeting and the outcome of the vote:
|
Description of Matter
|
Outcome of Vote
|
Votes For(1)
|
Votes Withheld/ Against(1)
|
|
1. Ordinary resolution to approve the election of the following eight nominees to serve as directors of Cynapsus for the ensuing year, or until their successors are duly elected or appointed subject to the provisions of the Canada Business Corporations Act and the by-laws of the Corporation:
|
|
|
|
|
Anthony Giovinazzo
|
Passed
|
23,967,491 (99.93%)
|
16,600 (0.07%)
|
|
Ronald Hosking
|
Passed
|
23,876,102 (99.55%)
|
107,989 (0.45%)
|
|
Tomer Gold
|
Passed
|
23,863,102 (99.50%)
|
120,989 (0.50%)
|
|
Nan Hutchinson
|
Passed
|
23,876,102 (99.55%)
|
107,989 (0.45%)
|
|
Perry Molinoff
|
Passed
|
23,876,102 (99.55%)
|
107,989 (0.45%)
|
|
Ilan Oren
|
Passed
|
23,876,102 (99.55%)
|
107,989 (0.45%)
|
|
Tamar Howson
|
Passed
|
23,876,102 (99.55%)
|
107,989 (0.45%)
|
|
Rochelle Stenzler
|
Passed
|
23,855,102 (99.46%)
|
128,989 (0.54%)
|
|
2. Ordinary resolution to approve the appointment of Ernst & Young, Chartered Professional Accountants, as auditors of Cynapsus for the ensuing year and to authorize the directors of Cynapsus to fix their remuneration as such.
|
Passed
|
41,629,601 (99.61%)
|
163,926 (0.39%)
|
|
3. Special resolution approving a consolidation of the common shares of Cynapsus and authorizing the directors of Cynapsus to select the consolidation ratio, in their sole discretion, within a range between one post-consolidation share for every five pre-consolidation shares and one post-consolidation share for every 25 pre-consolidation shares.
|
Passed
|
40,884,021 (97.82%)
|
909,506 (2.18%)
|
(1) On May 15, 2015, the Company consolidated the issued and outstanding common shares of the Company on the basis of one post-consolidation common share for 16 pre-consolidation common shares to facilitate the proposed listing on NASDAQ. Since the Meeting was held on May 7, 2015, the numbers reported are shown on a pre- 16:1 share consolidation basis.
About Cynapsus
Cynapsus is a specialty CNS pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with PD. The Company recently completed a Phase 2 clinical trial for its lead product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit a new drug application in 2016.
Contact Information
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
[email protected]
Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
[email protected]
Russo Partners LLC
Matt Middleman
(212) 845-4272
[email protected]
Forward-Looking Statements
This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, our focus on completing Phase 3 studies of APL-130277 over the next 12 to 16 months, pre-approval commercialization efforts in the U.S. and European market registration. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption “Risk Factors” in the Company’s Form 10-Q filed with the United States Securities and Exchange Commission (the “SEC”) on August 14, 2021 and its other filings and reports in the United States with the SEC available on the SEC’s web site, and in Canada with the various Canadian securities regulators, which are available online at www.sedar.com. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law.
Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.
***
